Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells-Reference-Cited by-同舟云学术

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Published:2020-08-14 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Zhu Chen,Song Zhili,Wang Anlai,Srinivasan Srimathi,Yang Guang,Greco Rita,Theilhaber Joachim,Shehu Elvis,Wu Lan,Yang Zhi-Yong,Passe-Coutrin Wilfried,Fournier Alain,Tai Yu-Tzu,Anderson Kenneth C.,Wiederschain Dmitri,Bahjat Keith,Adrián Francisco J.,Chiron Marielle

Funder

Sanofi

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference62 articles.

1. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond;van de Donk;Immunol Rev.,2016

2. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology;Malavasi;Physiol Rev.,2008

3. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member;Deaglio;J Immunol.,1998

4. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse;Muñoz;Blood.,2008

5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma;Krejcik;Blood.,2016

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging trends and therapeutic applications of monoclonal antibodies;Gene;2024-10

2. Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates;American Journal of Transplantation;2024-08

3. Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review;Pharmaceuticals;2024-07-15

4. Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38;Frontiers in Immunology;2024-06-25

5. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06